Orphazyme A/S Liabilities 2024

Orphazyme A/S Aktienanalyse

What does Orphazyme A/S do?

Orphazyme A/S is a Danish biopharmaceutical company specializing in the development of therapies for rare neurodegenerative diseases. They focus on researching amyloids, insoluble protein complexes found in various neurodegenerative diseases. Their business model involves developing and marketing therapeutic treatments for these rare neurodegenerative diseases. They specialize in four disease areas: Niemann-Pick disease type C (NPC), Gaucher disease, sporadic inclusion body myositis (sIBM), and amyotrophic lateral sclerosis (ALS). They concentrate on developing drugs that control lysosomal function and the breakdown of biocatalysts. Their advanced product, Arimoclomol, is currently being tested in a Phase 3 trial for the treatment of NPC disease. Orphazyme has collaborations with other companies and research institutions to advance their research and development efforts. These include a partnership with Sobi for the exclusive rights to market Arimoclomol in Europe and a collaboration with QIAGEN to develop biomarkers for diagnosing NPC disease. Overall, Orphazyme is a promising company focused on providing much-needed solutions for rare neurodegenerative diseases through their pipeline of therapies. They are well-positioned to become a leading player in the biopharmaceutical industry in the future. Orphazyme A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Orphazyme A/S's Liabilities

Orphazyme A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Orphazyme A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Orphazyme A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Orphazyme A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Orphazyme A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Orphazyme A/S Stock

What is the level of liabilities of Orphazyme A/S this year?

Orphazyme A/S has a debt balance of 5.07 M DKK this year.

What were the liabilities of Orphazyme A/S compared to the previous year?

The liabilities of Orphazyme A/S have increased by -68.02% dropped compared to the previous year.

What are the consequences of high debt for investors of Orphazyme A/S?

High liabilities can pose a risk for investors of Orphazyme A/S, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Orphazyme A/S?

Low liabilities mean that Orphazyme A/S has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Orphazyme A/S affect the company?

An increase in liabilities of Orphazyme A/S can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Orphazyme A/S affect the company?

A decrease in the liabilities of Orphazyme A/S can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Orphazyme A/S?

Some factors that can influence the liabilities of Orphazyme A/S include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Orphazyme A/S so important for investors?

The liabilities of Orphazyme A/S are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Orphazyme A/S take to modify the liabilities?

To change its liabilities, Orphazyme A/S can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Orphazyme A/S pay?

Over the past 12 months, Orphazyme A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orphazyme A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Orphazyme A/S?

The current dividend yield of Orphazyme A/S is .

When does Orphazyme A/S pay dividends?

Orphazyme A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orphazyme A/S?

Orphazyme A/S paid dividends every year for the past 0 years.

What is the dividend of Orphazyme A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orphazyme A/S located?

Orphazyme A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orphazyme A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orphazyme A/S from 6/22/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 6/22/2024.

When did Orphazyme A/S pay the last dividend?

The last dividend was paid out on 6/22/2024.

What was the dividend of Orphazyme A/S in the year 2023?

In the year 2023, Orphazyme A/S distributed 0 DKK as dividends.

In which currency does Orphazyme A/S pay out the dividend?

The dividends of Orphazyme A/S are distributed in DKK.